Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

294.98 +1.09 (+0.37%)

Official Closing Price Updated: 4:00 PM EST, Nov 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Market Sell-Off: Meet the Unstoppable Vanguard ETF Obliterating the S&P 500 in 2026 ↗

November 10, 2026

Value stocks are crushing growth stocks as investors sour on the artificial intelligence trade.

Via The Motley Fool

MarketBeat Week in Review – 11/2 - 11/6 ↗

November 07, 2026

Via MarketBeat

November 05, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

AbbVie (NYSE:ABBV): A Quality Investing Candidate With Caveats ↗

November 03, 2026

Via Chartmill

AbbVie (NYSE:ABBV) Q3 2026 Results In Line With Estimates as Guidance and Dividend Rise ↗

October 30, 2026

Via Chartmill

Cannabis Stocks’ Rally Is Narrow as Profitable Healthcare and Consumer Names Do the Heavy Lifting ↗

October 22, 2026

Via Chartmill

Topics Cannabis

3 Dividend Kings to Buy in November and Never Sell ↗

November 05, 2026

These are arguably among the most reliable dividend payers.

Via The Motley Fool

Topics Intellectual Property

2 Growth Stocks to Buy in November Without Any Hesitation ↗

November 05, 2026

They have both outperformed the broader equity market over the long run.

Via The Motley Fool

Juvederm vs Other Dermal Fillers: What Makes It Different and Who It Is For

November 04, 2026

Via BusinesNews Wire

AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test ↗

November 02, 2026

AbbVie posted Q3 revenue of $17.4 billion and raised EPS guidance as Skyrizi and Rinvoq offset Humira's decline, prompting analyst price target hikes and a stock move to fresh highs.

Via MarketBeat

Topics Intellectual Property

The Best Dividend Stocks to Buy With $5,000 in November ↗

November 02, 2026

AbbVie, J&J, and Medtronic remain reliable dividend plays in a rough market.

Via The Motley Fool

Topics Artificial Intelligence Economy

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027? ↗

November 02, 2026

AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.

Via The Motley Fool

Topics Intellectual Property

Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo ↗

November 02, 2026

AbbVie replaced one megablockbuster already. It may have found its next one.

Via The Motley Fool

Topics Intellectual Property

The top 5 analyst questions from AbbVie’s Q3 earnings call

November 01, 2026

AbbVie’s third quarter was marked by a positive market reaction, attributed to robust sales growth across its immunology and neuroscience portfolios. Managem...

Via StockStory

Topics Earnings

AbbVie: 3 Key Takeaways for Long-Term Investors ↗

October 31, 2026

Newer therapies must sustain double-digit growth to offset the impact of Humira's patent cliff, a test that shapes the dividend's long-term safety.

Via The Motley Fool

Topics Earnings Intellectual Property

Is AbbVie a Buy After Its Latest Earnings Report? ↗

October 31, 2026

Behind a doubling in adjusted EPS sits a more modest picture -- and a dividend streak worth understanding.

Via The Motley Fool

Topics Intellectual Property

ABBV Q3 deep dive: Immunology and neuroscience drive growth, pipeline progress continues

October 31, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street’s revenue expectations in Q3 2026, with sales up 10.3% year on year to $17.4 billion. Its non-GAAP ...

Via StockStory

AbbVie (ABBV) Q3 2026 Earnings Call Transcript ↗

October 30, 2026

Skyrizi and Rinvoq drive double-digit growth as management raises full-year guidance.

Via The Motley Fool

Topics Earnings

What AbbVie (ABBV) Said on Its Q3 Earnings Call ↗

October 30, 2026

AbbVie (NYSE:ABBV) reported third-quarter 2026 results above its guidance midpoint and raised its full-year revenue and adjusted earnings outlook, citing continued growth from its immunology and...

Via MarketBeat

Topics Earnings

AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates

October 30, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.3% year on year to $17.4 billion. Its non...

Via StockStory

AbbVie (ABBV) reports earnings tomorrow: what to expect

October 29, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings tomorrow before market open. Here’s what to expect. AbbVie beat analysts’ revenue expect...

Via StockStory

Topics Artificial Intelligence

Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy ↗

October 26, 2026

Despite its high price relative to earnings, AbbVie remains an attractive stock.

Via The Motley Fool

3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach ↗

October 23, 2026

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

Via MarketBeat

What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer ↗

October 22, 2026

They definitely matter... up to a point.

Via The Motley Fool

Topics Bonds Economy

Great News for AbbVie Stock Investors ↗

October 22, 2026

The company is gearing up for future major patent cliffs.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue? ↗

October 21, 2026

AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 20, 2026

AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.

Via The Motley Fool

Topics Intellectual Property

Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. ↗

October 20, 2026

This pharma leader has a history of outperforming during rising interest rates.

Via The Motley Fool

Topics Bonds Economy

2 High-Flying Dividend Stocks to Buy and Hold for a Decade ↗

October 19, 2026

They may just be getting started.

Via The Motley Fool

Topics Intellectual Property

Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It ↗

October 19, 2026

Buffett has warned about "gambling" in the market.

Via The Motley Fool

Topics Intellectual Property Retirement

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.